# Mirum Pharmaceuticals, Inc.: financial statements, quarterly

MIRM · Nasdaq · CIK 1759425 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mirm.md) · [Financials](/companies/mirm/financials.md) · [Filings](/companies/mirm/filings.md) · [Insiders](/companies/mirm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mirm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [47.7](/filings/0001759425-24-000038.md) | [69.6 d](/filings/0001759425-26-000013.md) | [69.2](/filings/0001759425-25-000032.md) | [77.9](/filings/0001759425-25-000041.md) | [90.4](/filings/0001759425-25-000054.md) | [99.4 d](/filings/0001759425-26-000013.md) | [112](/filings/0001759425-26-000037.md) | [128](/filings/0001759425-26-000045.md) | [133](/filings/0001759425-25-000054.md) | [149 d](/filings/0001759425-26-000013.md) | [160](/filings/0001759425-26-000037.md) | [176](/filings/0001759425-26-000045.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [36.5](/filings/0001759425-24-000038.md) | [46.2 d](/filings/0001759425-26-000013.md) | [45.6](/filings/0001759425-25-000032.md) | [49.2](/filings/0001759425-25-000041.md) | [50.5](/filings/0001759425-25-000054.md) | [56.8 d](/filings/0001759425-26-000013.md) | [57.7](/filings/0001759425-26-000037.md) | [63.3](/filings/0001759425-26-000045.md) | [61.9](/filings/0001759425-25-000054.md) | [74.1 d](/filings/0001759425-26-000013.md) | [96.3](/filings/0001759425-26-000037.md) | [81.5](/filings/0001759425-26-000045.md) |
| Operating income | $m | [(25.1)](/filings/0001759425-24-000038.md) | [(32.6) d](/filings/0001759425-26-000013.md) | [(26.5)](/filings/0001759425-25-000032.md) | [(24.2)](/filings/0001759425-25-000041.md) | [(12.7)](/filings/0001759425-25-000054.md) | [(24.2) d](/filings/0001759425-26-000013.md) | [(15.2)](/filings/0001759425-26-000037.md) | [(5.0)](/filings/0001759425-26-000045.md) | [2.6](/filings/0001759425-25-000054.md) | [(4.6) d](/filings/0001759425-26-000013.md) | [(789)](/filings/0001759425-26-000037.md) | [(42.5)](/filings/0001759425-26-000045.md) |
| Interest expense | $m | [3.6](/filings/0001759425-24-000038.md) | [3.6 d](/filings/0001759425-26-000013.md) | [3.6](/filings/0001759425-25-000032.md) | [3.6](/filings/0001759425-25-000041.md) | [3.6](/filings/0001759425-25-000054.md) | [3.6 d](/filings/0001759425-26-000013.md) | [3.6](/filings/0001759425-26-000037.md) | [3.6](/filings/0001759425-26-000045.md) | [3.6](/filings/0001759425-25-000054.md) | [3.6 d](/filings/0001759425-26-000013.md) | [3.6](/filings/0001759425-26-000037.md) | [2.6](/filings/0001759425-26-000045.md) |
| Income tax | $m | [0.2](/filings/0001759425-24-000038.md) | [0.2 d](/filings/0001759425-26-000013.md) | [0.6](/filings/0001759425-25-000032.md) | [0.6](/filings/0001759425-25-000041.md) | [0.3](/filings/0001759425-25-000054.md) | [(0.6) d](/filings/0001759425-26-000013.md) | [1.0](/filings/0001759425-26-000037.md) | [0.4](/filings/0001759425-26-000045.md) | [(0.3)](/filings/0001759425-25-000054.md) | [0.8 d](/filings/0001759425-26-000013.md) | [0.5](/filings/0001759425-26-000037.md) | [1.7](/filings/0001759425-26-000045.md) |
| Net income | $m | [(23.6)](/filings/0001759425-24-000038.md) | [(35.7) d](/filings/0001759425-26-000013.md) | [(25.3)](/filings/0001759425-25-000054.md) | [(24.6)](/filings/0001759425-25-000054.md) | [(14.2)](/filings/0001759425-25-000054.md) | [(23.8) d](/filings/0001759425-26-000013.md) | [(14.7)](/filings/0001759425-26-000045.md) | [(5.9)](/filings/0001759425-26-000045.md) | [2.9](/filings/0001759425-25-000054.md) | [(5.7) d](/filings/0001759425-26-000013.md) | [(790)](/filings/0001759425-26-000045.md) | [(67.2)](/filings/0001759425-26-000045.md) |
| Diluted EPS | $ per share | [(0.57)](/filings/0001759425-24-000038.md) | not reported | [(0.54)](/filings/0001759425-25-000032.md) | [(0.52)](/filings/0001759425-25-000041.md) | [(0.30)](/filings/0001759425-25-000054.md) | not reported | [(0.30)](/filings/0001759425-26-000037.md) | [(0.12)](/filings/0001759425-26-000045.md) | [0.05](/filings/0001759425-25-000054.md) | not reported | [(13.43)](/filings/0001759425-26-000037.md) | [(1.06)](/filings/0001759425-26-000045.md) |
| Basic EPS | $ per share | [(0.57)](/filings/0001759425-24-000038.md) | not reported | [(0.54)](/filings/0001759425-25-000032.md) | [(0.52)](/filings/0001759425-25-000041.md) | [(0.30)](/filings/0001759425-25-000054.md) | not reported | [(0.30)](/filings/0001759425-26-000037.md) | [(0.12)](/filings/0001759425-26-000045.md) | [0.06](/filings/0001759425-25-000054.md) | not reported | [(13.43)](/filings/0001759425-26-000037.md) | [(1.06)](/filings/0001759425-26-000045.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [303](/filings/0001759425-24-000038.md) | [286](/filings/0001759425-25-000014.md) | [303](/filings/0001759425-25-000032.md) | [233](/filings/0001759425-25-000041.md) | [223](/filings/0001759425-25-000054.md) | [223](/filings/0001759425-26-000013.md) | [212](/filings/0001759425-26-000037.md) | [228](/filings/0001759425-26-000045.md) | [282](/filings/0001759425-25-000054.md) | [297](/filings/0001759425-26-000045.md) | [325](/filings/0001759425-26-000037.md) | [331](/filings/0001759425-26-000045.md) |
| Current assets | $m | [389](/filings/0000950170-23-058228.md) | [388](/filings/0001759425-25-000014.md) | [389](/filings/0001759425-24-000019.md) | [368](/filings/0001759425-24-000031.md) | [387](/filings/0001759425-24-000038.md) | [393](/filings/0001759425-26-000013.md) | [411](/filings/0001759425-25-000032.md) | [453](/filings/0001759425-25-000041.md) | [531](/filings/0001759425-25-000054.md) | [550](/filings/0001759425-26-000045.md) | [569](/filings/0001759425-26-000037.md) | [636](/filings/0001759425-26-000045.md) |
| Total assets | $m | [651](/filings/0000950170-23-058228.md) | [647](/filings/0001759425-25-000014.md) | [652](/filings/0001759425-24-000019.md) | [661](/filings/0001759425-24-000031.md) | [668](/filings/0001759425-24-000038.md) | [671](/filings/0001759425-26-000013.md) | [690](/filings/0001759425-25-000032.md) | [726](/filings/0001759425-25-000041.md) | [785](/filings/0001759425-25-000054.md) | [843](/filings/0001759425-26-000045.md) | [891](/filings/0001759425-26-000037.md) | [1,045](/filings/0001759425-26-000045.md) |
| Current liabilities | $m | [74.7](/filings/0000950170-23-058228.md) | [87.1](/filings/0001759425-25-000014.md) | [106](/filings/0001759425-24-000019.md) | [112](/filings/0001759425-24-000031.md) | [116](/filings/0001759425-24-000038.md) | [127](/filings/0001759425-26-000013.md) | [128](/filings/0001759425-25-000032.md) | [145](/filings/0001759425-25-000041.md) | [160](/filings/0001759425-25-000054.md) | [206](/filings/0001759425-26-000045.md) | [273](/filings/0001759425-26-000037.md) | [223](/filings/0001759425-26-000045.md) |
| Total liabilities | $m | [382](/filings/0000950170-23-058228.md) | [398](/filings/0001759425-25-000014.md) | [417](/filings/0001759425-24-000019.md) | [432](/filings/0001759425-24-000031.md) | [436](/filings/0001759425-24-000038.md) | [445](/filings/0001759425-26-000013.md) | [457](/filings/0001759425-25-000032.md) | [471](/filings/0001759425-25-000041.md) | [493](/filings/0001759425-25-000054.md) | [528](/filings/0001759425-26-000045.md) | [648](/filings/0001759425-26-000037.md) | [1,055](/filings/0001759425-26-000045.md) |
| Shareholders' equity | $m | [269](/filings/0001759425-24-000038.md) | [249](/filings/0001759425-26-000013.md) | [235](/filings/0001759425-25-000054.md) | [229](/filings/0001759425-25-000054.md) | [232](/filings/0001759425-25-000054.md) | [226](/filings/0001759425-26-000045.md) | [233](/filings/0001759425-26-000045.md) | [255](/filings/0001759425-26-000045.md) | [292](/filings/0001759425-25-000054.md) | [315](/filings/0001759425-26-000045.md) | [242](/filings/0001759425-26-000045.md) | [(10.4)](/filings/0001759425-26-000045.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(18.2) d](/filings/0001759425-24-000038.md) | [(16.6) d](/filings/0001759425-26-000013.md) | [15.2](/filings/0001759425-25-000032.md) | [(3.8) d](/filings/0001759425-25-000041.md) | [4.0 d](/filings/0001759425-25-000054.md) | [(5.1) d](/filings/0001759425-26-000013.md) | [(2.0)](/filings/0001759425-26-000037.md) | [12.0 d](/filings/0001759425-26-000045.md) | [39.7 d](/filings/0001759425-25-000054.md) | [6.1 d](/filings/0001759425-26-000013.md) | [(229)](/filings/0001759425-26-000037.md) | [(44.3) d](/filings/0001759425-26-000045.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001759425-24-000038.md) | [0.0 d](/filings/0001759425-26-000013.md) | [0.0](/filings/0001759425-25-000032.md) | [0.8 d](/filings/0001759425-25-000041.md) | [0.2 d](/filings/0001759425-25-000054.md) | [0.0 d](/filings/0001759425-26-000013.md) | [0.0](/filings/0001759425-26-000037.md) | [0.1 d](/filings/0001759425-26-000045.md) | [0.2 d](/filings/0001759425-25-000054.md) | [0.6 d](/filings/0001759425-26-000013.md) | [0.7](/filings/0001759425-26-000037.md) | [0.0 d](/filings/0001759425-26-000045.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [34.9](/filings/0000950170-23-058228.md) | [37.7](/filings/0001759425-24-000019.md) | [38.1](/filings/0001759425-24-000031.md) | [41.1](/filings/0001759425-24-000038.md) | [46.9](/filings/0001759425-25-000032.md) | [47.2](/filings/0001759425-25-000041.md) | [47.8](/filings/0001759425-25-000054.md) | [48.9](/filings/0001759425-26-000037.md) | [49.7](/filings/0001759425-26-000045.md) | [57.0](/filings/0001759425-25-000054.md) | [58.9](/filings/0001759425-26-000037.md) | [63.4](/filings/0001759425-26-000045.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 64,932,203 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001759425-26-000045.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.